Compare NAT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAT | TBPH |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 914.8M | 824.9M |
| IPO Year | 1997 | 2013 |
| Metric | NAT | TBPH |
|---|---|---|
| Price | $5.71 | $16.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.25 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 5.2M | 510.5K |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $77.72 | $1.04 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $525.49 | ★ $8.03 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.39 | $8.32 |
| 52 Week High | $6.34 | $21.03 |
| Indicator | NAT | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 56.03 |
| Support Level | $3.21 | $13.41 |
| Resistance Level | $6.34 | $19.04 |
| Average True Range (ATR) | 0.32 | 0.51 |
| MACD | -0.02 | 0.30 |
| Stochastic Oscillator | 42.86 | 74.59 |
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.